Dr Reddy’s Laboratories on Thursday said that it has signed a deal to divest certain non-core brands of the company in the dermatology segment to Eris Lifesciences for Rs 275 crore.
The divested portfolio saw sales of Rs 60 crore as of IQVIA moving annual turnover (MAT) data December 2022.
M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), DRL said: “India is a focus market for us. We aspire to break into the top 5 in India. Today’s announcement is in line with our stated intention of pursuing a strategy that involves growing brands organically combined with acquisitions